JP2022553702A5 - - Google Patents
Info
- Publication number
- JP2022553702A5 JP2022553702A5 JP2022523574A JP2022523574A JP2022553702A5 JP 2022553702 A5 JP2022553702 A5 JP 2022553702A5 JP 2022523574 A JP2022523574 A JP 2022523574A JP 2022523574 A JP2022523574 A JP 2022523574A JP 2022553702 A5 JP2022553702 A5 JP 2022553702A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyldiyl
- peg
- amino
- pep
- thienoazepine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962926333P | 2019-10-25 | 2019-10-25 | |
| US62/926,333 | 2019-10-25 | ||
| US202062984184P | 2020-03-02 | 2020-03-02 | |
| US62/984,184 | 2020-03-02 | ||
| PCT/US2020/057167 WO2021081407A1 (en) | 2019-10-25 | 2020-10-23 | Thienoazepine immunoconjugates, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553702A JP2022553702A (ja) | 2022-12-26 |
| JP2022553702A5 true JP2022553702A5 (enExample) | 2023-10-20 |
| JP7709431B2 JP7709431B2 (ja) | 2025-07-16 |
Family
ID=73544268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523574A Active JP7709431B2 (ja) | 2019-10-25 | 2020-10-23 | チエノアゼピン、イムノコンジュゲート、及びそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11654199B2 (enExample) |
| EP (1) | EP4048315B1 (enExample) |
| JP (1) | JP7709431B2 (enExample) |
| KR (1) | KR20220088901A (enExample) |
| AU (1) | AU2020369652A1 (enExample) |
| BR (1) | BR112022007719A2 (enExample) |
| CA (1) | CA3155077A1 (enExample) |
| IL (1) | IL292396A (enExample) |
| MX (1) | MX2022004875A (enExample) |
| TW (1) | TWI857167B (enExample) |
| WO (1) | WO2021081407A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019000071A2 (pt) | 2016-07-07 | 2019-07-02 | Bolt Biotherapeutics Inc | conjugados adjuvantes de anticorpo |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| WO2021081402A1 (en) * | 2019-10-25 | 2021-04-29 | Bolt Biotherapeutics, Inc. | Macromolecule-supported thienoazepine compounds, and uses thereof |
| EP4048315B1 (en) | 2019-10-25 | 2025-03-12 | Bolt Biotherapeutics, Inc. | Thienoazepine immunoconjugates, and uses thereof |
| CA3176626A1 (en) * | 2020-05-08 | 2021-11-11 | David Dornan | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
| MX2023001679A (es) * | 2020-08-13 | 2023-02-22 | Bolt Biotherapeutics Inc | Inmunoconjugados de pirazolazepina y usos de estos. |
| US20250000995A1 (en) | 2021-10-29 | 2025-01-02 | Bolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof |
| EP4450496A4 (en) * | 2021-12-16 | 2025-12-24 | Duality Biologics Suzhou Co Ltd | TLR MODULATOR AND ITS USAGE |
| KR102970146B1 (ko) * | 2022-03-15 | 2026-05-28 | 에이치엘만도 주식회사 | 유압 밸브 블록 및 이를 포함하는 브레이크의 구동장치 |
| WO2024129956A1 (en) * | 2022-12-15 | 2024-06-20 | Bolt Biotherapeutics, Inc. | Thienoazepine immunoconjugates, and uses thereof |
| WO2026050213A1 (en) * | 2024-08-27 | 2026-03-05 | Usbolt Biotherapeutics, Inc. | Tlr agonist immunoconjugates and uses thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US723288A (en) | 1901-10-26 | 1903-03-24 | Harry South Lewis | Cipher-key for cryptographic codes. |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| ATE370961T1 (de) | 1998-05-06 | 2007-09-15 | Genentech Inc | Reinigung von antikörpern durch ionenaustauschchromatographie |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| AU5345901A (en) | 2000-04-13 | 2001-10-30 | Univ Rockefeller | Enhancement of antibody-mediated immune responses |
| WO2005086875A2 (en) | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| US20070014795A1 (en) | 2004-12-30 | 2007-01-18 | Dhodapkar Madhav V | Compositions and methods for enhanced dendritic cell maturation and function |
| AU2006312148B2 (en) | 2005-11-07 | 2012-04-12 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
| NZ569204A (en) | 2005-12-21 | 2012-03-30 | Micromet Ag | Pharmaceutical compositions with resistance to soluble CEA - comprising antibodies that bind to CD3 and CEA |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| BRPI0818780A2 (pt) | 2007-10-19 | 2015-04-22 | Genentech Inc | Anticorpo anti-tenb2 planejados por cisteína e conjugados de medicamento com anticorpos |
| CN105669553A (zh) | 2009-08-18 | 2016-06-15 | 文蒂雷克斯药品公司 | 作为toll样受体调节剂的取代的苯并氮杂* |
| JP5845899B2 (ja) | 2010-02-04 | 2016-01-20 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| EP2640727B1 (en) | 2010-11-17 | 2015-05-13 | Genentech, Inc. | Alaninyl maytansinol antibody conjugates |
| KR101981342B1 (ko) | 2011-03-02 | 2019-05-22 | 로슈 글리카트 아게 | Cea 항체 |
| ES2672695T3 (es) | 2011-08-04 | 2018-06-15 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
| MX348579B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| KR101968499B1 (ko) | 2011-08-04 | 2019-04-12 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| CN103764825B (zh) | 2011-08-04 | 2015-09-02 | 东丽株式会社 | 癌的治疗和/或预防用药物组合物 |
| ES2739380T3 (es) | 2012-02-21 | 2020-01-30 | Toray Industries | Composición farmacéutica para el tratamiento del cáncer |
| AU2013223143B2 (en) | 2012-02-21 | 2017-12-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| IN2014KN01714A (enExample) | 2012-02-21 | 2015-10-23 | Toray Industries | |
| MX357505B (es) | 2012-02-21 | 2018-07-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
| WO2014014082A1 (ja) | 2012-07-19 | 2014-01-23 | 東レ株式会社 | 癌の検出方法 |
| CA2879185C (en) | 2012-07-19 | 2021-08-24 | Toray Industries, Inc. | Method for detecting cancer |
| PT3199552T (pt) | 2012-11-20 | 2020-03-25 | Sanofi Sa | Anticorpos anti-ceacam5 e suas utilizações |
| CA2918989C (en) | 2013-08-09 | 2021-11-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| HRP20210977T1 (hr) | 2014-02-10 | 2021-09-17 | Merck Patent Gmbh | Ciljano inhibiranje tgf beta |
| JP6805142B2 (ja) | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| WO2018079740A1 (ja) | 2016-10-28 | 2018-05-03 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
| CA3049791A1 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| US20210154316A1 (en) | 2018-05-17 | 2021-05-27 | Bolt Biotherapeutics, Inc. | Immunoconjugates |
| EP3983080A1 (en) | 2019-06-13 | 2022-04-20 | Bolt Biotherapeutics, Inc. | Macromolecule-supported aminobenzazepine compounds |
| JP2022537158A (ja) | 2019-06-13 | 2022-08-24 | ボルト バイオセラピューティクス、インコーポレーテッド | アミノベンズアゼピン化合物、イムノコンジュゲート、及びそれらの使用 |
| EP4048315B1 (en) | 2019-10-25 | 2025-03-12 | Bolt Biotherapeutics, Inc. | Thienoazepine immunoconjugates, and uses thereof |
| WO2021081402A1 (en) | 2019-10-25 | 2021-04-29 | Bolt Biotherapeutics, Inc. | Macromolecule-supported thienoazepine compounds, and uses thereof |
-
2020
- 2020-10-23 EP EP20811787.9A patent/EP4048315B1/en active Active
- 2020-10-23 KR KR1020227017386A patent/KR20220088901A/ko not_active Withdrawn
- 2020-10-23 AU AU2020369652A patent/AU2020369652A1/en not_active Abandoned
- 2020-10-23 WO PCT/US2020/057167 patent/WO2021081407A1/en not_active Ceased
- 2020-10-23 JP JP2022523574A patent/JP7709431B2/ja active Active
- 2020-10-23 IL IL292396A patent/IL292396A/en unknown
- 2020-10-23 TW TW109136997A patent/TWI857167B/zh not_active IP Right Cessation
- 2020-10-23 BR BR112022007719A patent/BR112022007719A2/pt unknown
- 2020-10-23 US US17/078,467 patent/US11654199B2/en active Active
- 2020-10-23 CA CA3155077A patent/CA3155077A1/en active Pending
- 2020-10-23 MX MX2022004875A patent/MX2022004875A/es unknown
-
2023
- 2023-03-06 US US18/118,105 patent/US12465653B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022537158A5 (enExample) | ||
| JP2022549510A5 (enExample) | ||
| JP2023524271A5 (enExample) | ||
| JP2022554094A5 (enExample) | ||
| JP2022546110A5 (enExample) | ||
| JP2024099041A5 (enExample) | ||
| IL312845B1 (en) | Extacan derivatives, charge-linkers, and their conjugates | |
| JP2024523453A5 (enExample) | ||
| JP2025041725A5 (enExample) | ||
| JP2023553421A5 (ja) | 抗ｃｅａ免疫複合体、及びその使用 | |
| JP2024545233A5 (enExample) | ||
| JP5503872B2 (ja) | 核酸系代謝拮抗剤の高分子誘導体 | |
| JP6704900B2 (ja) | ポリオキサゾリン抗体薬物複合体 | |
| CN112752759A (zh) | 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物及其方法与用途 | |
| RU2748992C2 (ru) | Системы доставки для контролируемого высвобождения лекарственного средства | |
| JP2024501453A5 (enExample) | ||
| WO2017165851A1 (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| JP2020506951A5 (enExample) | ||
| JP2020531471A5 (enExample) | ||
| JP2023545096A5 (enExample) | ||
| JP2023552791A5 (enExample) | ||
| JP2023552792A5 (enExample) | ||
| JP2023552790A5 (enExample) | ||
| JP2024511088A5 (enExample) | ||
| JP2022516427A5 (enExample) |